New Lattice CrossLink-NX FPGAs Bring Power and Performance Leadership to Embedded Vision and Edge AI Applications
Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today announced the first FPGA developed on its new Lattice Nexus™ FPGA platform, CrossLink-NX™. This new FPGA provides the low power, small form factor, reliability, and performance that developers need to create innovative embedded vision and AI solutions for communications, compute, industrial, automotive, and consumer systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005349/en/
The new CrossLink-NX FPGA from Lattice Semiconductor (Graphic: Business Wire)
According to Patrick Moorhead, President and Founder of Moor Insights & Strategy, “Technology trends like 5G connectivity, cloud-based analytics, factory automation and the smart home are driving demand for embedded vision solutions that support machine learning. However, the data latency, cost and privacy issues associated with cloud-based ML analytics have sparked interest among developers in moving more data processing from the cloud to the Edge. But doing so requires OEMs have access to Edge AI/ML inferencing solutions that offer high performance data processing, low power operation, and a small form factor.”
FPGAs are a compelling hardware platform for embedded vision and AI applications, as they perform functions in parallel. This parallel architecture significantly accelerates certain processing workloads, including data inferencing.
“Embedded vision systems are growing in complexity; many systems today use multiple image sensors, displays and cameras. Implementing such systems at the Edge, where device size and power consumption are critical, adds even more design complexity,” said Bill Pu, Co-Founder and President, Leopard Imaging. “With their very low power consumption, small size, high-performance interfaces, and robust software and IP library, Lattice CrossLink-NX FPGAs let us quickly and easily develop different video signal bridging, aggregation and splitting applications for our industrial and automotive customers using just one device, saving us significant development time and resources.”
The CrossLink-NX family was designed using the new Lattice Nexus platform, which combines a 28 nm FD-SOI manufacturing process with a new, Lattice-designed, FPGA fabric architecture optimized for low power operation in a small form factor.
“Not only does CrossLink-NX lead in power consumption, form factor, reliability and performance in comparison to similar competing FPGAs, it is also supported by a robust library of design software, IP blocks and application reference designs,” said Gordon Hands, Director of Product Marketing, Lattice Semiconductor. “These make it quick and easy for developers to integrate CrossLink-NX FPGAs into new or existing Edge designs.”
Key features of the CrossLink-NX include:
- Low power – built on the Lattice Nexus FPGA platform, CrossLink-NX provides up to a 75 percent reduction in power consumption compared to competing FPGAs of a similar class.
- High reliability – CrossLink-NX has a Soft Error Rate (SER) up to 100 times lower than similar FPGAs in its class, making it a compelling solution for mission critical applications that must operate safely and reliably. The initial CrossLink-NX device is designed to support ruggedized environments found in outdoor, industrial, and automotive applications.
Performance – CrossLink-NX delivers enhanced performance enabled by three key elements:
- Fast I/O support – CrossLink-NX FPGAs are well-suited for embedded vision applications thanks to support for multiple fast I/Os, including MIPI, PCIe and DDR3 memory.
- Instant on performance – to better support applications where a long system boot time is unacceptable, such as industrial motor control, CrossLink-NX enables ultra-fast I/O configuration in 3 ms and total device configuration in less than 15 ms.
- High memory to logic ratio – to efficiently power AI inferencing in Edge devices, CrossLink-NX features 170 bits of memory for every logic cell, the highest memory to logic ratio in its class, providing 2x the performance compared to prior generations.
- Small form factor – to support customer system miniaturization, the first CrossLink-NX device is available in a 6 x 6 mm form factor which is up to ten times smaller than similar competing FPGAs in its class.
- Software tools and IP – in addition to its new Lattice Radiant 2.0 design software, Lattice offers a robust library of popular IP cores including interfaces like MIPI D-PHY, PCIe, SGMII and OpenLDI, and demos for common embedded vision applications such as 4:1 image sensor aggregation.
Originally scheduled for availability in 2020, Lattice is releasing CrossLink-NX ahead of schedule and is already sampling devices with select customers. For more information, please visit www.latticesemi.com/CrossLink-NX.
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world.
Lattice Semiconductor Corporation, Lattice Semiconductor (& design) and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom